Archive
FTSE 100 closes in the red as the investor gloom continues
Britain's blue-chip index finished around 45 points lower, or 0.62%, at 7,236 on the day
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 16 of 55
AstraZeneca wins injunction preventing former executive from joining GSK
AstraZeneca secured a victory in its battle with GSK in its executive tug of war at the last moment - at least for now
AstraZeneca's Farxiga successfully used to treat heart failure
The new indication could increase Farxiga's addressable market by 50%
AstraZeneca looking for bolt-on acquisitions
Pascal Soriot said the FTSE 100 giant is particularly interested in firms that specialise in oncology and cardiovascular treatments
AstraZeneca breast cancer drug performs well in latest trial
The results of the confirmatory assessment mirrored earlier positive data
AstraZeneca chemotherapy signed off for use in people with lung cancer
The US Food & Drug Administration has provided its seal of approval for Enhertu
AstraZeneca breast cancer drug gets the green light
The Anglo-Swedish drugs giant has hailed Enhertu as as potentially transformational treatment
AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilience
Instead of dropping by up to a quarter, sales of Vaxzevria will now be flat
Archive
FTSE 100 closes higher on final session of July as Wall Street extends post-earnings run
At the close, the UK blue-chip index was up 78.18 points, or 1.1% at 7,423.23, just below the morning peak of 7,441.20 and well above the opening low of 7,345.25
AstraZeneca delivers a triple dose of drug updates
It has received two drug approvals and a priority review
AstraZeneca acquires blood cancer specialist TeneoTwo for up to US$1.2bn
By redirecting the body's natural immune response to target B-cell malignancies, the TNB-486 drug being developed by TeneoTwo could be used alone or in combination, adding a new weapon to AstraZeneca's haematology portfolio
AstraZeneca hails phase III success of drug for rare disease amyloid polyneuropathy
It will file a new drug application later this year
AstraZeneca downgraded by UBS on lack of catalysts until 2023
In the longer term, the pharma analysts believe that the drug company “has the potential to build out a platform of antibody-drug conjugates” of which Enhertu is the first
Archive
FIVE at FIVE: De Pfeffel kerfuffle; Musk in handbrake turn; Countryside Partnerships under siege; AstraZeneca finds market hard to please
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news.
AstraZeneca wows peers but misses out on post-Jubilee bounce
Analysts expected a rally in the pharma group's shares following its critical update on breast cancer drug Enhertu at the ASCO conference this weekend
AstraZeneca beats profit and revenue forecasts; to open new R&D site
The pharma group still expects full-year revenue percentage growth in the high teens
AstraZeneca says liver cancer treatment combo accepted for US priority review
According to a phase III trial, patients treated with a combination of tremelimumab and Imfinzi experienced a 22% reduction in the risk of death
AstraZeneca a 'buy' for Deutsche Bank after lung cancer drug granted priority review
Deutsche Bank gave the drug-maker a price target of 11,500p, approximately 10% higher than Tuesday’s closing price
AstraZeneca cancer drug receives priority FDA review as data points to its potential in lung cancer
AstraZeneca said it believes Enhertu could become the standard of care for a certain group of lung cancer sufferers for whom there is no targeted treatment
Are AstraZeneca PLC shares a 'buy'? This leading bank is a fan
Deutsche Bank has raised its price target on stock in the Anglo-Swedish group